Key points are not available for this paper at this time.
Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.
Building similarity graph...
Analyzing shared references across papers
Loading...
Monika E. Hegi
University Hospital of Lausanne
Annie‐Claire Diserens
SIB Swiss Institute of Bioinformatics
Thierry Gorlia
European Organisation for Research and Treatment of Cancer
New England Journal of Medicine
University of Calgary
University Medical Center Utrecht
University of Tübingen
Building similarity graph...
Analyzing shared references across papers
Loading...
Hegi et al. (Wed,) studied this question.
synapsesocial.com/papers/69d78e5bb843b2be99490442 — DOI: https://doi.org/10.1056/nejmoa043331